This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
NICE. NICE consults on draft guidance for new cystic fibrosis treatment. Media Release : 23 Mar 2016. Available from: URL: http://www.nice.org.uk
Rights and permissions
About this article
Cite this article
UK NICE does not recommend lumacaftor-ivacaftor for CF. PharmacoEcon Outcomes News 750, 37 (2016). https://doi.org/10.1007/s40274-016-2960-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2960-1